MCL1 and glioma: Finally, to confirm the therapeutic efficacy of targeting the ROS1–JAK–STAT axis in KLC1-ROS1 fusion-harboring gliomas, the antitumor efficacies of lorlatinib, ruxolitinib, and the Mcl-1 inhibitor subtoclax, in combination with TMZ, were investigated.